Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Rodríguez-Lescure Á, Gallego J, Garcia-Alfonso P, Massuti B, Márquez R, Calvo L, Sánchez-Rovira P, Antón A, Chacón JI, Ciruelos E, Ponce JJ, Santaballa A, Valladares-Ayerbes M, Dueñas MR, Alonso V, Aparicio J, Encinas S, Robles L, Escudero MJ, Caballero R, Bezares S, García-Ortiz MV, Morales-Ruiz T, de la Haba-Rodriguez J

Open source

DOI: 10.1007/s12094-025-04113-7
Published: 2026 Jan
Container: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12094-025-04113-7,
  title = {Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.},
  author = {Rodríguez-Lescure Á and Gallego J and Garcia-Alfonso P and Massuti B and Márquez R and Calvo L and Sánchez-Rovira P and Antón A and Chacón JI and Ciruelos E and Ponce JJ and Santaballa A and Valladares-Ayerbes M and Dueñas MR and Alonso V and Aparicio J and Encinas S and Robles L and Escudero MJ and Caballero R and Bezares S and García-Ortiz MV and Morales-Ruiz T and de la Haba-Rodriguez J},
  year = {2026},
  journal = {Clinical \& translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
  doi = {10.1007/s12094-025-04113-7},
  url = {https://doi.org/10.1007/s12094-025-04113-7}
}

RIS

TY  - JOUR
TI  - Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
AU  - Rodríguez-Lescure Á
AU  - Gallego J
AU  - Garcia-Alfonso P
AU  - Massuti B
AU  - Márquez R
AU  - Calvo L
AU  - Sánchez-Rovira P
AU  - Antón A
AU  - Chacón JI
AU  - Ciruelos E
AU  - Ponce JJ
AU  - Santaballa A
AU  - Valladares-Ayerbes M
AU  - Dueñas MR
AU  - Alonso V
AU  - Aparicio J
AU  - Encinas S
AU  - Robles L
AU  - Escudero MJ
AU  - Caballero R
AU  - Bezares S
AU  - García-Ortiz MV
AU  - Morales-Ruiz T
AU  - de la Haba-Rodriguez J
PY  - 2026
JO  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
DO  - 10.1007/s12094-025-04113-7
UR  - https://doi.org/10.1007/s12094-025-04113-7
ER  -

APA

Á, R., J, G., P, G., B, M., R, M., L, C., P, S., A, A., JI, C., E, C., JJ, P., A, S., M, V., MR, D., V, A., J, A., S, E., L, R., MJ, E., R, C., S, B., MV, G., T, M., & J, D. L. H. (2026). Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-025-04113-7

Source records

pubmed · retrieved 2026-09-26T17:10:36.866Z